Mara R. Holton, MD, is the CEO of Anne Arundel Urology group in Annapolis, Maryland, where she has served in this role for the past 5 years. Board-certified by the American Board of Urology and licensed in the state of Maryland, Dr Holton is clinically focused on the care of women’s urological and pelvic floor health. She is the founder and director of the Women’s Wellness Center at Anne Arundel Urology, and is a member of the American Urological Association and the Large Urology Group Practice Association. Dr Holton received her medical degree from Temple University School of Medicine in Philadelphia, Pennsylvania, and completed her surgical and urology training at the University of Maryland Medical Center in Baltimore.

Jason M. Hafron, MD, is a partner and the director of research at the Michigan Institute of Urology, P.C. in Troy; associate professor of urology, William Beaumont School of Medicine, Oakland University; and the director of robotic surgery at Beaumont Hospital Royal Oak. Dr Hafron specializes in the minimally invasive treatment of cancers involving the prostate, kidney, and bladder utilizing laparoscopic and robotic surgery. He received his medical degree from Loyola University Chicago-Stritch School of Medicine, and completed his general surgery and urology residency at Albert Einstein College of Medicine, Montefiore Medical Center. He completed an advanced laparoscopic and robotic surgery fellowship at the Cleveland Clinic Foundation, Glickman Urological and Kidney Institute.

Tamra E. Lewis, MD, FACS, is a private practice urologist at Comprehensive Urologic Care in the suburbs of Chicago. She received her MD from the University of Iowa College of Medicine, completed surgical and urology residencies at the University of Nebraska, and completed a fellowship in female urology and voiding dysfunction at Metro Urology in Minneapolis/St. Paul. Dr Lewis is among the first group of urologists to receive board certifications in female pelvic medicine and reconstructive surgery. Her professional interests include management of incontinence, voiding dysfunction, and urinary tract infections. She is involved organizations that include the American Urological Society, Society of Women in Urology and Chicago Urologic Society, and is a member of the LUPGA Forward Committee.

David O. Sussman, DO, FACOS, is clinical associate professor, Department of Surgery, Division of Urology, and section head of Female Urology and Voiding Dysfunction at Rowan University in Glassboro, New Jersey. He is chief of urology for Jefferson New Jersey, a 3-hospital health system in southern New Jersey. Dr Sussman is actively engaged in clinical research involving BPH, urinary incontinence and voiding dysfunction. He has served as a speaker, moderator and symposium chairman for many major urology symposia, seminars and conferences, lectured nationally and internationally on the evaluation/treatment of OAB/incontinence, and has authored or co-authored several journal articles, posters and abstracts. He received his medical degree from the University of New England in Biddeford, Maine.

Jennifer U. Miles-Thomas, MD, FPMRS, is the medical director of the Pelvic Health program at Chesapeake Regional Healthcare in Virginia Beach, Virginia, and is assistant professor of urology at Eastern Virginia Medical School. Dr Miles-Thomas provides specialized care in female reconstructive surgery, pelvic prolapse, incontinence, complicated urinary disorders, and disorders of the urinary system due to neurologic disease. She earned her medical degree from Northwestern University Feinberg School of Medicine in Chicago, Illinois and completed a general surgery internship at the Johns Hopkins Hospital in Baltimore, Maryland, where she also completed her urology residency and fellowships in female urology and endourology at the James Buchanan Brady Urological Institute.

Neal D. Shore, MD, FACS, is the medical director for the Carolina Urologic Research Center and practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr Shore has conducted more than 350 clinical trials that focus mainly on GU oncology, has served on the executive boards of the Society of Urologic Oncology, Bladder Cancer Advocacy Network and the Society of Urologic Oncology Clinical Trials Consortium, and is immediate past president of the Large Urology Group Practice Association. He is a founder for the CUSP Clinical Trials Consortium and DASHKO, large urology practices data registries. He has over 150 peer-reviewed publications, several book chapters, and is a peer reviewer for numerous high-impact medical journals. He earned his MD from Duke University Medical School and general surgery/urology residency at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center.

Scott A. MacDiarmid, MD, is director of the Alliance Urology Specialists Bladder Control and Pelvic Pain Center in Greensboro, North Carolina, and is a clinical professor in the Department of Urology, University of North Carolina, Chapel Hill. Dr MacDiarmid’s clinical, educational and academic expertise is in male and female voiding dysfunction, neurogenic bladder, and complex lower urinary tract and pelvic floor reconstruction. He has authored or co-authored numerous books, book chapters and journal articles, and is recognized nationwide as a leader in his field. He completed fellowships in reconstructive urology and urodynamics at Duke University Medical Center in Durham, North Carolina, the University of Otago in Christchurch, New Zealand, and the University of Sheffield in England.

Britt McDermott is the chief executive officer for Urology of Indiana in Greenwood, where she has served in her current role since 2015. Prior to joining Urology of Indiana, she served as the vice president of Indiana operations for a large multispecialty group. In addition to her health care leadership experience, she has spent more than 20 years providing accounting, tax and consulting services exclusively to health care providers. Ms McDermott is a graduate of Indiana University, Bloomington, and is a certified public accountant.

Earl L. Walz is chief executive officer of The Urology Group in Cincinnati, Ohio. Prior to joining The Urology Group, he was chief operating officer of the Urology Specialists, served as chief administrative consultant at the Northern Kentucky Multi Specialty Practice, and was chief operating officer of the Hoxworth Blood Center in Cincinnati. A certified medical practice executive, he is a member of several corporate and government medical advisory boards, and is a co-founder of the Large Urology Group Practice Association. He received his master’s degree in business administration from Xavier University in Cincinnati and a bachelor of science degree from the Northern Kentucky University in Highland Heights.

Twila Puritty, MBA, is the chief executive officer of Wichita Urology Group in Wichita, Kansas. Having more than 25 years of experience in health care leadership, Mrs Puritty’s professional passions are facilitating growth initiatives, enhancing collection efforts through microanalysis and maximizing shareholder wealth. In her 5 years with Wichita Urology Group, the practice has grown by building a free-standing radiation oncology facility, adding a successful clinical trial program, implementing Xofigo infusions and in-office dispensing, and developing successful equipment and building leasing LLCs. Prior to joining Wichita Urology Group, Mrs Puritty served as the lead nonphysician executive for radiology groups in Florida, California, Oklahoma, Nebraska and Kansas.

Kenneth M. Kernen, MD, is a partner in, and the director of clinical research for, the Michigan Institute of Urology in Troy. Dr Kernen received his medical degree from Wayne State University School of Medicine in Detroit, Michigan, completed his urologic residency at William Beaumont Hospital in Royal Oak, Michigan, and his urologic oncology fellowship at Baylor College of Medicine in Houston, Texas. He is the chief of urology at William Beaumont Hospital, Troy, where he is also the founding director of the Prostate and Urologic Cancer Multidisciplinary Clinic and clinical chair of the Robotic Surgical Committee. Additionally, he is co-director of the Urology Center for Excellence at Beaumont Health Systems.

Daniel J. George, MD, is a professor of medicine and surgery in the Divisions of Medical Oncology and Urology at Duke University School of Medicine in Durham, North Carolina. He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute, where he is the director of genitourinary (GU) oncology. Dr George’s areas of research include new drug development and biomarkers of GU cancers with an emphasis on signal transduction pathways and angiogenesis. He leads the Duke site for the Department of Defense Prostate Cancer Clinical Trials Consortium, specializing in Phase I and II studies in prostate cancer. Dr George is an internationally recognized clinical researcher and thought leader in GU malignancies, with over 150 peer-reviewed publications.